

**Note:**

An easy-to-use site-directed mutagenesis method with a designed restriction site for convenient and reliable mutant screening*

Bao-zhong ZHANG^{1,2}, Xin ZHANG¹, Xiao-ping AN¹, Duo-liang RAN²,
Yu-sen ZHOU¹, Jun LU^{†‡3}, Yi-gang TONG^{†‡1}

(¹State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China)

(²College of Veterinary Science, Xinjiang Agricultural University, Urumqi 830052, China)

(³Tumor Biotherapy Ward, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China)

[†]E-mail: tong.yigang@gmail.com; lujun98@gmail.com

Received Nov. 17, 2008; Revision accepted Mar. 3, 2009; Crosschecked Apr. 24, 2009

Abstract: Site-directed mutagenesis (SDM) has been a very important method to probe the function-structure relationship of proteins. In this study, we introduced an easy-to-use, polymerase chain reaction (PCR)-based SDM method for double-stranded plasmid DNA, with a designed restriction site to ensure simple and efficient mutant screening. The DNA sequence to be mutated was first translated into amino acid sequence and then the amino acid sequence was reversely translated into DNA sequence with degenerate codons, resulting in a large number of sequences with silent mutations, which contained various restriction endonuclease (RE) sites. Certain mutated sequence with an appropriate RE site was selected as the target DNA sequence for designing a pair of mutation primers to amplify the full-length plasmid via inverse PCR. The amplified product was 5'-phosphorylated, circularized, and transformed into an *Escherichia coli* host. The transformants were screened by digesting with the designed RE. This protocol uses only one pair of primers and only one PCR is conducted, without the need for hybridization with hazardous isotope for mutant screening or subcloning step.

Key words: Site-directed mutagenesis (SDM), Restriction endonuclease, Mutant screening

doi:10.1631/jzus.B0820367

Document code: A

CLC number: Q3

Site-directed mutagenesis (SDM) has a variety of applications and is extensively used in molecular biology. Over the last three decades, various SDM methods have been described (Nagy *et al.*, 2004; Zheng *et al.*, 2004; Seyfang and Jin, 2004; An *et al.*, 2005; Wei *et al.*, 2004; Jin *et al.*, 2007; Heckman and Pease, 2007; Tseng *et al.*, 2008; Li *et al.*, 2008; Chapnik *et al.*, 2008) and some commercial SDM kits based on these techniques are available. The SDM techniques can be grouped into two major categories: polymerase chain reaction (PCR)-based and non-PCR-based. The PCR-based SDM methods are used

more frequently than the non-PCR-based methods. Rabhi *et al.* (2004) have introduced an inverse PCR-based SDM method with forward and reverse primers to amplify the full-length plasmid. The blunt-ended amplification products are 5'-phosphorylated, self-ligated, and transformed into *Escherichia coli*. The design of this protocol is straightforward and the procedures are brief. However, hybridization has to be conducted for mutant screening because the difference between the original sequence and the target sequence is only one or a few base pairs, which makes the most common screening method, i.e., restriction digestion, not applicable. The laborious hybridization step with hazardous isotope deters researchers from adopting this simple mutagenesis method. Here we present a novel mutagenesis strategy, designed restriction endonuclease-assisted

[‡] Corresponding authors

* Project supported by the Hi-Tech Research and Development (863) Program of China (No. 2007AA02Z151) and the National Natural Science Foundation of China (No. 30872223)

mutagenesis (DREAM), which introduces one or more restriction endonuclease cleavage site(s) into proximity of the mutation site without altering the target amino acid sequence, so as to simplify the mutant screening and make the method more practical.

The principle of the suggested SDM method is outlined in Fig.1. For an amino acid sequence to be mutated, its target sequence is reversely translated into DNA sequences using degenerate codons, resulting in many silently mutated sequences containing various restriction endonuclease cleavage sites. Certain sequence with an appropriate restriction site is selected as the target DNA sequence for designing mutagenic primers. The full-length plasmid DNA was





Fig.1 Schematic diagram of the site-directed mutagenesis (SDM) method

(a) Designing of target DNA sequence. To introduce an appropriate restriction site into the target sequence, the target amino acid sequence is reverse-translated into a silently mutated sequence. Mutagenic primers for inverse PCR to amplify the full-length plasmid are selected according to silently mutated DNA sequence. Origin: the original DNA sequence to be mutated; Target: the designed target DNA sequence with a designed restriction site for rapid mutant screening; AA.1: amino acid sequence deduced from the original DNA sequence; AA.2: the target amino acid sequence. The mutated nucleotides are underlined, and the designed restriction site (*Xho*I) is indicated by an open box; (b) Flow chart of the mutagenesis procedures. PNK: polynucleotide kinase; RE: restriction endonuclease; PCR: polymerase chain reaction

amplified by inverse PCR with a high-fidelity DNA polymerase and the amplified product was 5'-phosphorylated by T4 polynucleotide kinase and then self-ligated. After transformation into an *E. coli* host, the transformants were readily screened by digesting with the introduced restriction endonuclease.

To demonstrate the validity of the suggested method, we designed a point mutation in plasmid pcDNA3.1-pIgR, which is approximately 8 kb in size and expresses human polymeric immunoglobulin receptor (*pIgR*) by the cytomegalovirus (CMV) early promoter and enhancer. We performed the SDM to introduce an amino acid substitution (Lys to Glu) in *pIgR* cDNA on this plasmid (Fig.1). To simplify the restriction site designing, we made use of a free online tool WatCut (http://watcut.uwaterloo.ca/watcut/watcut/template.php?act=silent_new) to display all the silently mutated sequences containing restriction sites. From the displayed sequences, we chose a sequence containing an *Xho*I site as our target sequence. Based on this sequence, we designed a pair of inverse PCR primers (Fig.1). The sequences of the forward and reverse primers are 5'-TCG AGG TCA GCC AGG GTC-3' and 5'-GGC TGA CAT CAA AGG ACA GG-3', respectively. Since the inverse PCR was conducted with a high-fidelity DNA polymerase with proofreading 3'-5' exonuclease activity, there were no 3'-A tails generated. So the primers were designed by directly copying the target sequence without overlapping region included (Fig.1).

A standard PCR reaction was then carried out with a 50- μ l total reaction mixture containing 1 \times HF PCR buffer (Mg²⁺ Plus, Invitrogen), 200 μ mol/L dNTPs, 200 nmol/L forward and reverse primers, 1 ng template DNA (pcDNA3.1-pIgR), and 1 U PhusionTM high-fidelity DNA polymerase (New England Bio-Labs). PCR reaction was carried out with a GeneAmp PCR system 2400 (Perkin Elmer, Foster City, CA, USA). The PCR parameters were as follows: pre-denaturation at 98 $^{\circ}$ C for 30 s; followed by 35 cycles of denaturation at 98 $^{\circ}$ C for 10 s, annealing at 65 $^{\circ}$ C for 20 s, and polymerization at 72 $^{\circ}$ C for 150 s; and a final extension step at 72 $^{\circ}$ C for 10 min. The PCR products were then separated on 1% (w/v) agarose gel electrophoresis (Fig.2a) and recovered using a glass milk DNA extraction kit (BioDev, Beijing, China). A phosphorylation reaction of the PCR products was carried out at 37 $^{\circ}$ C for 30 min in 50- μ l

total reaction mixture containing 1× T4 polynucleotide kinase buffer (50 mmol/L Tris-HCl, 10 mmol/L MgCl₂, and 5 mmol/L DL-dithiothreitol (DTT)), 5 U T4 polynucleotide kinase (PNK, New England BioLabs), and 200 μmol/L adenosine triphosphate (ATP). After an inactivation step at 70 °C for 5 min to inactivate the T4 polynucleotide kinase, the PCR products were circularized using 350 U T4 DNA ligase (Takara) at 12 °C for 16 h. 10 μl of the ligation mixture was then used to transform competent *E. coli* Top10 (Invitrogen) and the transformation mixture was plated on a Luria-Bertani (LB) agar plate containing 100 μg/ml ampicillin and incubated at 37 °C.

Ten colonies were picked up randomly and the plasmid DNA was extracted and digested by the designed restriction enzyme *Xho*I along with another enzyme *Bgl*III. Of the 10 plasmids, 3 displayed the desired electrophoresis pattern (Fig.2b). DNA sequencing analysis confirmed that all of the three clones contained the correctly mutated DNA sequence (Fig.3b). To check whether unwanted mutations were generated by PCR in the *pIgR* genes and in the regulation elements, we sequenced a region of about 3600 bp of a clone, which encompasses the whole *pIgR* open reading frame, the CMV early promoter and enhancer, and the bovine growth




Fig.2 Amplification and screening of target plasmid DNAs were subjected to 1% (w/v) agarose gel electrophoresis and visualized with ethidium bromide staining. (a) Amplification of the full-length target plasmid; (b) Restriction analysis of the target plasmids. Recombinant plasmids and the original plasmid as a control are digested by designed endonuclease *Xho*I combined with *Bgl*III. PCR: the amplified products; M: DNA molecular marker (1 kb ladder); C: the original plasmid pcDNA3.1-pIgR as a control




Fig.3 DNA sequence analysis of the original and target plasmids

(a) The original plasmid DNA sequence with arrows to show the nucleotides to be mutated; (b) The target plasmid with arrows to show the target nucleotides and an open box to show the designed restriction site *Xho*I

hormone (BGH) polyadenylation site. The results show that no additional mutations were caused by PCR.

In summary, we have developed a novel SDM strategy that makes use of the degenerate amino acid codons to introduce a restriction enzyme cleavage site into the proximity of the mutation site for easy and rapid mutant screening, thus eliminating the necessity for arduous hybridization screening using hazardous isotopes. The whole mutagenesis procedure is simple and no commercial kits are needed. Since the mutagenesis is carried out directly on double stranded plasmid DNA, the resulted plasmid is fit for direct use without any further subcloning. This mutagenesis protocol can not only introduce point mutations, but also be used to generate insertions and deletions. To perform this PCR-based SDM, a high-fidelity thermostable DNA polymerase should be used to avoid unwanted mutations that could be resulted from DNA polymerization with error-prone thermostable DNA polymerase like *Taq*. We recommend the New England BioLabs Phusion™ DNA polymerase, because it has a very low mutation rate ($4.4 \times 10^{-7} \text{ bp}^{-1}$), which is 50 times lower than that of the *Taq* polymerase and 6 times lower than that of the *Pfu* polymerase. The very high fidelity of Phusion™ DNA polymerase may

account for the results that there were no unwanted mutations in our experiments. Other virtues of Phusion™ polymerase include high speed and high yield, which makes it easy to amplify a DNA of up to 20 kb according to the manufacturer's manual. Since most plasmids are shorter than 20 kb, this SDM protocol could be applied virtually to all plasmids.

References

- An, Y., Ji, J., Wu, W., Lv, A., Huang, R., Wei, Y., 2005. A rapid and efficient method for multiple-site mutagenesis with a modified overlap extension PCR. *Appl. Microbiol. Biotechnol.*, **68**(6):774-778. [doi:10.1007/s00253-005-1948-8]
- Chapnik, N., Sherman, H., Froy, O., 2008. A one-tube site-directed mutagenesis method using PCR and primer extension. *Anal. Biochem.*, **372**(2):255-257. [doi:10.1016/j.ab.2007.07.020]
- Heckman, K.L., Pease, L.R., 2007. Gene splicing and mutagenesis by PCR-driven overlap extension. *Nat. Protoc.*, **2**(4):924-932. [doi:10.1038/nprot.2007.132]
- Jin, C., Cai, X., Ma, H., Xue, Y., Yao, J., Yao, X., 2007. An efficient site-directed mutagenesis method for ColE1-type ori plasmid. *Anal. Biochem.*, **363**(1):151-153. [doi:10.1016/j.ab.2006.12.007]
- Li, X., Qiu, Y., Shen, Y., Ding, C., Liu, P., Zhou, J., Ma, Z., 2008. Splicing together different regions of a gene by modified polymerase chain reaction-based site-directed mutagenesis. *Anal. Biochem.*, **373**(2):398-400. [doi:10.1016/j.ab.2007.10.021]
- Nagy, Z.B., Felfoldi, F., Tamas, L., Puskas, L.G., 2004. A one-tube, two-step polymerase chain reaction-based site-directed mutagenesis method with simple identification of the mutated product. *Anal. Biochem.*, **324**(2):301-303. [doi:10.1016/j.ab.2003.09.009]
- Rabhi, I., Guedel, N., Chouk, I., Zerria, K., Barbouche, M.R., Dellagi, K., Fathallah, D.M., 2004. A novel simple and rapid PCR-based site-directed mutagenesis method. *Mol. Biotechnol.*, **26**(1):27-34. [doi:10.1385/MB:26:1:27]
- Seyfang, A., Jin, J.H., 2004. Multiple site-directed mutagenesis of more than 10 sites simultaneously and in a single round. *Anal. Biochem.*, **324**(2):285-291. [doi:10.1016/j.ab.2003.10.012]
- Tseng, W.C., Lin, J.W., Wei, T.Y., Fang, T.Y., 2008. A novel megaprimered and ligase-free, PCR-based, site-directed mutagenesis method. *Anal. Biochem.*, **375**(2):376-378. [doi:10.1016/j.ab.2007.12.013]
- Wei, D., Li, M., Zhang, X., Xing, L., 2004. An improvement of the site-directed mutagenesis method by combination of megaprimer, one-side PCR and *DpnI* treatment. *Anal. Biochem.*, **331**(2):401-403. [doi:10.1016/j.ab.2004.04.019]
- Zheng, L., Baumann, U., Reymond, J.L., 2004. An efficient one-step site-directed and site-saturation mutagenesis protocol. *Nucleic. Acids Res.*, **32**(14):e115. [doi:10.1093/nar/gnh110]